Clinical Trials in San Francisco

Showing 461-480 of 6,211 trials

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

NCT07238322

This study is designed to prospectively analyze \[18F\]FET PET image data obtained retrospectively in the routine clinical care of glioma patients. The study will analyse the data from participants with grade (1-4) glioma after primary treatment according to local clinical practice and with suspicion of progression/recurrence on magnetic resonance imaging (MRI).

Retrospective StudyGliomaBrain Neoplasms

Telix Pharmaceuticals (Innovations) Pty Limited400 participantsStarted Sep 2025

San Francisco, California, United States • Essen, Germany • Tübingen, Germany +1 more locations

RECRUITINGPHASE3< 1 mile

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

NCT06246916

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs. * How much study drug is in the blood at different times. * Whether the body makes antibodies against the study drugs (which could make the drug less effective or could lead to side effects)

Melanoma

Regeneron Pharmaceuticals560 participantsStarted Sep 2024

Chandler, Arizona, United States • Gilbert, Arizona, United States • Tucson, Arizona, United States +105 more locations

[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Find Trials by Condition in San Francisco

Prenatal Transplantation for Fetuses With Fanconi Anemia

DAY101 In Gliomas and Other Tumors

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

J-Valve Transfemoral Pivotal Study

Longitudinal Early-onset Alzheimer's Disease Study Protocol

Alcohol-ROC-Training

Product Surveillance Registry

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Zenith® Fenestrated+ Clinical Study

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab